{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:11:01Z","timestamp":1790809861275,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Indisulam possesses anticancer properties through down\u2010regulation of various cell\u2010cycle checkpoint molecules, thereby blocking the phosphorylation of retinoblastoma protein and inducing p53 and p21. Indisulam exhibits synergy with nucleoside analogs and topoisomerase inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      The authors designed a phase 2 study of indisulam in combination with idarubicin and cytarabine in patients who had relapsed\/refractory acute myeloid leukemia AML and high\u2010risk myelodysplastic syndrome. In stage 1, patients received intravenous indisulam at 400\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on days 1 and 8 of a 28\u2010day cycle. If they had no response, then patients received same dose schedule of indisulam followed by intravenous idarubicin 8\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      daily for 3 days and cytarabine 1.0\u2009g\/m\n                      <jats:sup>2<\/jats:sup>\n                      over 24 hours daily on days 9 through 12 (for those aged\u2009&lt;\u200960 years) or days 9 through 11 (for those aged\u2009&gt;\u200960 years) of a 28\u2010day cycle. Primary endpoints included the overall response rate, and secondary objectives included overall survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Forty patients were enrolled. Of the 37 evaluable patients, 31 received indisulam with chemotherapy. Of these, 11 (35%) responded for a median duration of 5.3 months. The estimated 1\u2010year overall survival rate was 51% for responders compared with 8 % for nonresponders (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.001). The most common grade \u22653 nonhematologic toxicities were electrolyte abnormalities (50%) and febrile neutropenia (28%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      The combination of indisulam with idarubicin and cytarabine yielded a 35% response rate in heavily pretreated patients with AML. With emerging data identifying the expression of DCAF15 (DDB1 and CUL4\u2010associated factor 15) as a potential biomarker for activity, the combination of indisulam with idarubicin and cytarabine should be studied in a biomarker\u2010driven trial or in patients who have splicing factor mutations.\n                      <jats:bold>\n                        <jats:italic>Cancer<\/jats:italic>\n                        2018;124:2758\u201065.\n                      <\/jats:bold>\n                      \u00a9\n                      <jats:italic>2018 American Cancer Society<\/jats:italic>\n                      .\n                      <jats:bold>\n                        <jats:italic>Cancer<\/jats:italic>\n                        2018;124:2758\u20102765\n                      <\/jats:bold>\n                      . \u00a9\n                      <jats:italic>2018 American Cancer Society<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.31398","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T19:34:56Z","timestamp":1523907296000},"page":"2758-2765","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["Final results of a phase 2, open\u2010label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high\u2010risk myelodysplastic syndrome"],"prefix":"10.1002","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1159-883X","authenticated-orcid":false,"given":"Rita","family":"Assi","sequence":"first","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Uehara","sequence":"additional","affiliation":[{"name":"Tsukuba Research Laboratories, Eisai Company, Ltd Tsukuba Ibaraki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Owa","sequence":"additional","affiliation":[{"name":"Tsukuba Research Laboratories, Eisai Company, Ltd Tsukuba Ibaraki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-604538"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.242"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.027"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23858"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9902638"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00275-1"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.005"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604300"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1844-8"},{"key":"e_1_2_8_11_1","first-page":"153a","article-title":"A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5\u2010fluorouracil\u2010based chemotherapy [abstract]","volume":"21","author":"Mainwaring PN","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25263"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.093765"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V88.2.756.bloodjournal882756","article-title":"A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]","volume":"88","author":"Estey E","year":"1996","journal-title":"Blood"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21187"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.030"},{"key":"e_1_2_8_20_1","first-page":"275","article-title":"Profiling novel sulfonamide antitumor agents with cell\u2010based phenotypic screens and array\u2010based gene expression analysis","volume":"1","author":"Yokoi A","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5293.1672"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.12.1501"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200211000-00002"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010608317361"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.09.062"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20141450"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3755"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2363"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:18:47Z","timestamp":1760275127000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,16]]},"references-count":28,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1002\/cncr.31398"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31398","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,16]]},"assertion":[{"value":"2017-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}